Neurology
-
Randomized Controlled Trial Multicenter Study Comparative Study
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). What are the long-term effects of alemtuzumab treatment, received 36 to 48 months previously, on relapse and disability in early, active RRMS? This study provides evidence of the effectiveness of alemtuzumab in reducing the relapse rate and accumulation of disability compared with interferon β-1a (IFNβ-1a) through extended follow-up (up to 60 months from baseline). ⋯ This study provides Class III evidence that alemtuzumab is more effective than interferon β-1a in reducing relapses and disability in patients with RRMS in a long-term follow-up of a rater-blinded, randomized clinical trial with 59.5% of patients participating in the extended follow-up period.
-
Randomized Controlled Trial
θ-burst stimulation of the left hemisphere accelerates recovery of hemispatial neglect.
Cortico-cortical circuits originating from the posterior parietal cortex (PPC) of the intact left hemisphere (LH) may become hyperexcitable in patients with hemispatial neglect due to a right hemispheric (RH) stroke. ⋯ This study provides Class III evidence that left posterior parietal cortex theta-burst stimulation improves hemispatial neglect for up to 2 weeks after treatment.
-
Comment Letter Randomized Controlled Trial
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
-
Randomized Controlled Trial
Intrathecal effects of daclizumab treatment of multiple sclerosis.
We previously reported that daclizumab, a humanized monoclonal antibody against CD25, reduced contrast-enhancing lesions (CEL) in patients with multiple sclerosis (MS) who were suboptimal responders to interferon-β and that this response correlated with expansion of CD56(bright) NK cells. These data have been reproduced in a placebo-controlled multicenter trial (CHOICE study). The current study investigates whether daclizumab monotherapy reduces CEL in untreated patients with relapsing-remitting MS (RRMS) and the effects of daclizumab on the intrathecal immune system. ⋯ The study provides Class III evidence that daclizumab reduces the number of contrast-enhancing lesions in treatment-naive patients with RRMS over a 54-week period.
-
Randomized Controlled Trial Multicenter Study
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
To assess the effects of treatment with onabotulinumtoxinA (Botox, Allergan, Inc., Irvine, CA) on health-related quality of life (HRQoL) and headache impact in adults with chronic migraine (CM). ⋯ This study provides Class 1A evidence that onabotulinumtoxinA treatment reduces headache impact and improves HRQoL.